Joshua Friedman, MD, PhD

Spyre Therapeutics
Waltham, MA, United States

Senior Vice President, Clinical Development

Presentation(s):

• 2035: Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggest A Potential for Q3M or Q6M Maintenance Dosing for Rheumatologic Disease

  Tuesday, October 28, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): Spyre Therapeutics: Employee (Ongoing), Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing)